Drug-Eluting Stents
Economic Model Presented at TCT 2010 Suggests That the Use of CYPHER Drug Eluting Stent May Result in Substantial Cost Savings When Compared to Other Drug Eluting Stents
PRESS RELEASE
New analysis presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2010) in Washington, DC, indicates that the broad use of CYPHER Sirolimus-eluting coronary stent in patients with diabetes would result in substantial cost savings, as compared to the use of everolimus-eluting stents (EES), paclitaxel-eluting stents (PES), or zotarolimus-eluting stents (ZES). Diabetic patients are a population at elevated risk of needing repeat coronary procedures and also pose a significant cost burden to the health care system.
Medtronic’s Resolute Drug-Eluting Stent Shows Strong Performance in Second ‘All Comers’ Study
PRESS RELEASE
Coronary artery disease, a leading cause of death and poor quality of life worldwide, runs the gamut from simple to complex, which complicates the daily practice of interventional cardiology. New clinical data from a second, large international study that enrolled “all comers,” regardless of disease complexity and comorbidities, again demonstrated the strong performance of the Resolute drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), for patients across this continuum.
Boston Scientific’s Platinum QCA study of the Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Element Stent
PRESS RELEASE
Boston Scientific’s Promus Element stent wins additional CE Mark
Boston Scientific Corp. (NYSE:BSX) received CE Mark approval in the European Union for a new indication for its everolimus-eluting Promus Element coronary stent system.
Cardiologists may now deploy the platinum chromium alloy drug-eluting stents in patients with concomitant diabetes mellitus and in those experiencing an acute myocardial infarction, or heart attack.
Medtronic achieves across the pond
Medtronic Inc. (NYSE:MDT) announced a pair of accomplishments for two of its cardiac treatment devices in Europe.
The Minneapolis-based medical device behemoth won CE Mark approval in the European Union for its CoreValve transcatheter aortic valve implantation system.
The company said the device, which has not yet been approved by the Food & Drug Administration for use in the U.S., increases the accuracy of the deployment of its CoreValve artificial aortic heart valve.
Study: African-Americans treated with drug-eluting stents at higher risk for blood clots
African-Americans have double the risk for blood clots after being treated with drug-eluting stents, according to a a study published in Circulation: Journal of the American Heart Assn.
In as few as 30 days, race was the strongest predictor for clotting after stents were implanted, the study showed.
The researchers analyzed data from 7,236 patients who, between mid-2003 through 2008, were treated with stents coated with clot-prevention drugs.
Cordis touts the 10-year anniversary of the first Cypher implantation
Cordis Corp. is touting the 10-year anniversary of the first implantation of a drug-eluting stent, saying a now-85-year-old patient showed nearly complete coverage a decade after receiving the first Cypher stent.
The Johnson & Johnson (NYSE:JNJ) subsidiary said a 75-year-old woman was implanted with the sirolimus-eluting device in 1999, to treat a single lesion in the left anterior descending artery. In 2009, angiography, IVUS examination and an optical coherence tomography test showed "a complete coverage of over 90 percent of the analyzed struts," according to a press release.
Medtronic wins CE Mark for new drug-eluting stent system
Medtronic Inc. (NYSE:MDT) won CE Mark approval in the European Union for its new drug-eluting coronary stent system.
The Minneapolis-based medical device giant said the device’s new design gives it superior mobility within a patient’s vasculature.
Medtronic said the stent’s new "continuous sinusoid technology" gives the device significantly more deliverability than alternative stents when administered with the its MicroTrac delivery system.
Cordis wins again on appeal in ‘heated’ fight over Cypher stents
Cordis does not use any heat to bond metal to polymer in its Cypher stents and that’s more than cool with a federal appeals court.
A three-judge panel for the U.S. Court of Appeals for the Federal Circuit (CAFC) this week affirmed a lower court decision that found Cypher did not infringe on patents held by Effingham, Ill.-based MarcTec LLC — in effect, siding with the Johnson & Johnson unit because of the way it assembles the drug-eluting stent.
Boston Scientific commences yet another stent trial
Boston Scientific Corp. (NYSE:BSX) has begun enrolling patients for a clinical trial of its "fourth-generation" drug-eluting coronary stent.
The new device, entitled the Synergy, has a bioabsorbable polymer and everolimus drug coating and the same alloy design used in the company’s Promus Element stent.